Residency · Residency · Pathology
Ductal Carcinoma In Situ: Grading and Margin Assessment
Introduction
Ductal carcinoma in situ (DCIS) is a non-invasive neoplastic proliferation of epithelial cells confined within the basement membrane of the mammary ducts. It accounts for approximately 20-25% of screen-detected breast cancers. Accurate grading, margin assessment, and biomarker evaluation are critical for guiding surgical and radiation therapy decisions.
Histologic Architecture
DCIS displays several architectural patterns, often occurring in combination within the same specimen. The comedo pattern features central necrosis with calcification and high-grade nuclei, making it the most aggressive pattern. Cribriform DCIS shows rigid, punched-out (cookie-cutter) spaces within a monomorphic cell population. The micropapillary pattern consists of bulbous tufts projecting into duct lumens without fibrovascular cores. Solid DCIS fills ducts completely with a solid proliferation of neoplastic cells. The papillary pattern has true fibrovascular cores lined by neoplastic epithelium and characteristically lacks myoepithelial cells on those cores.
Nuclear Grading
The Van Nuys / consensus grading system classifies DCIS into three nuclear grades.
| Grade | Nuclear Size | Chromatin / Nucleoli | Architecture | Necrosis | Calcification Type |
|---|---|---|---|---|---|
| 1 (Low) | 1.5–2× RBC | Evenly spaced, inconspicuous nucleoli | Cribriform, micropapillary | Rare | Psammomatous/laminated |
| 2 (Intermediate) | Moderate pleomorphism | Intermediate | Variable | May be present | Variable |
| 3 (High) | >2.5× RBC | Coarse chromatin, prominent nucleoli | Comedo, solid | Comedo necrosis | Amorphous/linear |
Low-Grade (Grade 1)
Low-grade DCIS contains small, uniform nuclei measuring 1.5 to 2 times the size of a red blood cell, with inconspicuous nucleoli and evenly spaced chromatin. It often adopts a cribriform or micropapillary architecture, and the associated calcifications are typically psammomatous or laminated.
Intermediate-Grade (Grade 2)
Intermediate-grade DCIS shows moderate nuclear pleomorphism, with features falling between low and high grade. Necrosis may or may not be present.
High-Grade (Grade 3)
High-grade DCIS features large, pleomorphic nuclei exceeding 2.5 times the size of a red blood cell, with prominent nucleoli, coarse chromatin, and frequent mitoses. It is often accompanied by comedo necrosis with associated amorphous or linear calcifications and carries the highest risk of recurrence and progression to invasive carcinoma.
Comedonecrosis
Comedonecrosis refers to central luminal necrosis, often accompanied by dystrophic calcification. Historically designated as comedo-type DCIS, it is associated with higher grade and more aggressive behavior. Regardless of the nuclear grade assigned, the presence or absence of comedonecrosis should always be documented in the report.
Margin Assessment
Why Margins Matter
Adequate margins are the most important modifiable factor for reducing local recurrence. The 2016 SSO/ASTRO/ASCO consensus recommends a minimum margin of 2 mm for DCIS treated with breast-conserving surgery and radiation.
Reporting Margins
The pathology report should state the closest margin and its distance in millimeters. When DCIS extends to the inked margin, the margin is reported as positive (involved). The extent of DCIS at or near the margin should be documented, and correct orientation of the specimen with adherence to inking protocols is critical for meaningful margin assessment.
Challenges
DCIS often grows in a discontinuous, segmental pattern along the duct system, which complicates margin evaluation. Specimen processing with serial sectioning perpendicular to margins is the preferred approach, and re-excision should be considered for margins less than 2 mm.
Size Estimation
The maximum extent of DCIS should be measured using the number of involved slides and the intervening distances between them. Three-dimensional reconstruction may be necessary for large or multifocal DCIS. Size influences staging and drives treatment decisions such as the choice between mastectomy and lumpectomy.
Biomarker Testing in DCIS
ER/PR status should be reported on all DCIS, as most low- and intermediate-grade DCIS is ER-positive. HER2 testing is not routinely required but may be positive in approximately 60-70% of high-grade DCIS. Multigene assays such as the Oncotype DX DCIS score can aid in radiation therapy decisions for selected patients.
Differential Diagnosis
Atypical ductal hyperplasia (ADH) is distinguished from low-grade DCIS by its smaller size, defined as less than 2 mm or involving fewer than 2 duct spaces. Lobular carcinoma in situ (LCIS) is E-cadherin negative and has different biology and management. Cancerization of lobules describes DCIS extending into lobules, which does not change the diagnosis. Paget disease of the nipple represents DCIS extending to the nipple epidermis.
Clinical Pearls
The pathology report for DCIS should always include nuclear grade, presence of necrosis, architectural pattern, size, and margin status. The 2 mm margin threshold for DCIS is distinct from the "no ink on tumor" standard applied to invasive carcinoma. High-grade DCIS with comedo necrosis carries the highest risk of recurrence and progression to invasive disease. Microinvasion, defined as invasion extending 1 mm or less beyond the basement membrane, should be carefully sought and reported, as sentinel lymph node biopsy may be indicated when it is found.
References
- Morrow M, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. J Clin Oncol. 2016;34(33):4040-4046.
- Allred DC. Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr. 2010;2010(41):134-138.
- Collins LC, et al. Pathology of ductal carcinoma in situ. Surg Clin North Am. 2018;98(4):677-691.
- Lester SC, et al. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med. 2009;133(1):15-25.